Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026

Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...

Sarepta shares tumble on trial failure, weak Elevidys outlook

Sarepta Therapeutics' shares plunged nearly 30% on Tuesday as the failure of two of its approved drugs in a key trial and ...
Investor's Business Daily on MSN

Sarepta Loses Almost A Third Of Its Value On Failed Tests, Gene Therapy Outlook

Sarepta stock crashed Tuesday after the biotech company said two of its muscular dystrophy drugs failed confirmatory tests.

Sarepta Therapeutics Inc (SRPT) Q3 2025 Earnings Call Highlights: Resilient Revenue Amidst ...

Despite disruptions and restructuring costs, Sarepta Therapeutics Inc (SRPT) showcases strong revenue performance and ...

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Sarepta Therapeutics, Inc. (NASDAQ: SRPT) stock fell sharply Tuesday following disappointing results from a key clinical trial and ongoing concerns about its drug pipeline. However, "Pharma Bro" ...

Sarepta’s stock plummets as disappointing trial data raise questions on DMD drug’s success

Shares of Sarepta Therapeutics Inc. plunged in extended trading Monday after the biotechnology company disclosed ...

Sarepta Therapeutics shares plunge after disappointing trial data

Sarepta Therapeutics shares plunged 37% after two Duchenne muscular dystrophy drugs failed a key trial, raising regulatory ...

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Sarepta's Duchenne trial missed its main goal but showed trends favoring treatment; Q3 earnings topped estimates amid ...

Top Stock Movers Now: Palantir, Sarepta Therapeutics, Denny's, and More

Major U.S. equities indexes were lower at midday Tuesday, with Palantir Technologies leading tech stocks lower.